Recent Updates
Recently added Catalysts

Cannabidiol

Phase 2

Menstrual Discomfort | Small molecule | Other |Canopy Growth Corporation Common Shares|Last Updated: Jan 10, 2023

Success Probability
Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
Premium
Market & Valuation
rNPV $3.2B
Market Size $9.4B
Revenue Basis $1.6B
Competitors 6
Premium
Trial Design
UNCONTROLLED
Total Trials1
Total Enrollment33
FDA Designations
No designations recorded
Clinical Trials (1)
NCT IDTitlePhaseStatusEnrollmentVelocityDesignStartCompletionLast UpdatedSitesCountries
NCT05679830The Effects of CBD Isolate on Menstrual-Related SymptomsPHASE2 COMPLETED 33Sep 1, 2020Sep 1, 2021Jan 10, 2023 -
Unlock Drug Trial Details
Study Design & Arms
Interventions
NameTypeDescription
CannabidiolDRUGCannabidiol is a non-psychoactive cannabinoid obtained from the cannabis plant.
Unlock Study Design Details